

EXHIBIT 2029

**Cephalon Exhibit 2029
Fresenius v. Cephalon
IPR2016-00098**

THISSEN Laboratories s.a.

Rue de la Papyr e 2-6
 B-1420 BRAINE L'ALLEUD
 Tel: 32-2-386.12 11
 Fax: 32-2-385 17 82

SDX 105 FOR INJECTION

BATCH : 03H08



TEST PARAMETER	TEST METHOD	RELEASE SPECIFICATION	RESULTS
General and specific characteristics			
Appearance	Visual examination	White, microcrystalline lyophilisate	Complies
Uniformity of dosage units	USP <905>	Complies	Complies
Constituted solution	USP <1>	Complies	Complies
pH value after reconstitution	USP <791>	2.5 - 3.5	3.2
Identity			
Bendamustine hydrochloride	HPLC	Complies with standard	Complies
Assay			
Bendamustine hydrochloride	HPLC	100.0 mg / vial 95.0 - 105.0 mg/vial	98.4
Purity			
Water content	USP <921> method 1	Max 2.5 %	0.9
Related substances	HPLC		
HP1		Max 3.3 %	1.8
HP2		Max 0.5 %	ND
HP3		Max 0.1 %	ND
NP1		Max 0.5 %	<LOQ
BM1 EE		Max 0.6 %	0.2
BM1 DIMER		Max 0.7 %	0.3
BM1 DCE		Max 0.1 %	ND
HBI		Max 0.5 %	ND
Not identified single peaks		Max 0.1 %	ND
Sum of not identified peaks		Max 0.5 %	ND
Sum of all secondary peaks		Max 5.0 %	2.3
Sterility		USP <71>	Sterile
Bacterial endotoxines	USP <85>	Max 0.5 I.U. / mg	< 0.192
Particulate matter	USP <788>	Complies	Complies

Confirma

CERTIFICATE OF ANALYSIS		
Bendamustin 100 mg for injection, Batch no. 03H08		
Expiry Date: 08.2005		
TI no.: 3.0		
Test parameter	Specification	Result
General characteristics		
Appearance	white, microcrystalline lyophilisate	complies
Average mass	198.0 – 242.0 mg	221.6 mg
Uniformity of mass	complies with Ph. Eur. 2.9.5	complies
Solubility	soluble within 5 minutes without residues	complies
Clarity after reconstitution	clear	complies
Colour after reconstitution	≤ B 6	complies
pH-value after reconstitution	2.5 – 3.5	3.2
Identity		
- Chloride	positive	complies
- Bendamustine hydrochloride	complies with standard	complies
Purity		
Related substances		
- HP 1	max. 3.5 %	1.8 %
- HP 2	max. 0.5 %	n.d.
- NP 1	max. 0.5 %	<LOQ
- BM1EE	max. 0.5 %	0.2 %
- HBI	max. 0.5 %	n.d.
- Not identified singel peaks	max. 0.2 %	n.d.
- Sum of not identified peaks	max. 0.5 %	0.3 %
- Sum of all secondary peaks	max. 5.0 %	2.3 %
Water content	max. 2.5 %	0.9 %
Sterility	sterile, complies with Ph. Eur. 2.6.1	complies
Endotoxins	not more than 0.5 I.U. / mg	complies
Assay		
Bendamustine hydrochloride	100.0 mg / vial (limits: 95.0 – 105.0 mg / vial)	98.4 mg / vial
<p>We herewith confirm that this batch was manufactured and tested in accordance with the relevant GMP requirements.</p> <p>Status: Approved for clinical trials</p>		

Munich, October 2nd, 2003

B. Unterlinner
 Dr. Unterlinner
 Head of Product Release/QC

Fuchs
 Fuchs
 Product Documentation/QC

Administrative headquarters: Berg-am-Larm-Strasse 129 D-81673 München Telefax: +49(0)89 45 44-13 29	Operations: Weihenstephaner Strasse 28 D-81673 München Telefax: +49(0)89 45 44-15 95	Telephone: +49(0)89 45 44-01 V.A.T. No. DE 811188277	E-mail: info@fujisawa-deutschland.de Website: www.fujisawa-deutschland.de	Dresdner Bank München acct. # 03 017 825 00 Bank ID Code: 700 800 00 SWIFT address: DRES DE FF 700	Stadtsparkasse München acct. # 39-180 039 Bank ID Code: 701 500 00 SWIFT-address: SSKM DE MM AXX
--	---	---	--	---	---

Company Seat: München - Incorporated at the Court Registry in München HRB 67 708 - President: Dr. Wolfgang Tröbel - Executive Vice President: Dipl.-Kfm. Wilfried ...